Saudi Myeloma المجموعة السعودية لأبحاث المايلوما

The official twitter account of the Saudi Myeloma Working Group (SMWG)

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

#NewProfilePic

[Ghazi Alotaibi @Ghazialot]

Join us tonight:

https://t.co/vV02PURvP8

@SaudiMyeloma

[Ben Derman @bdermanmd]

TecLille: Tec+Dara in transplant ineligible NDMM
n=37; median age 73 (!)
Very high MRD negativity rates even at 6 months!
Very interesting correlatives, including clonotypic peptide sequencing and sBCMA.
No progressions. No deaths.
14% grade 3+ infections (nearly everyone got IVIg starting within first cycle).

If this regimen can be so well tolerated upfront even in older adults, that bodes very well for the future of bispecific antibodies in frontline therapy.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASH25 MajesTEC-3 will transform #MMsm care even more than CAR-T for many 🌏 pts in near future.

But to shout (again) from rooftop: to do tec-dara safely, use primary IVIG/SCIG prophylaxis!

Excellent suppl fig in @NEJM illustrating why OS curves crossed and how they fixed it.

[Vincent Rajkumar @VincentRK]

Impressive. Bela-KPd in patients relapsing after CART in relapsed myeloma. #ASH25 @bdermanmd

-Lower dose of Belantamab every 8 weeks — this is critical.
-82% response rate
-Median PFS 15 months

[NEJM @NEJM]

Presented at #ASH25:

In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. Full RedirecTT-1 phase 1b–2 study results: https://t.co/KX8DYXj5tK

@ASH_hematology

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

https://t.co/FP7rGbpsye

[Vincent Rajkumar @VincentRK]

Updated mSMART guidelines on treatment of newly diagnosed myeloma.

Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant.

https://t.co/R4hz7ulYPb

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

A new webinar ����

https://t.co/tKGxFVRuGA

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

Join us for the Saudi Myeloma Working Group Virtual Series (Wave 8)
🗓️ Sunday, Aug 31 | 8 PM (KSA) | 2 CME
🎤 Prof. Shaji Kumar @myelomaMD (Mayo Clinic)
Topic: Positioning T-Cell Engagers in Relapsed/Refractory Myeloma
💻 Don’t miss it!

https://t.co/C3gmzl3X1q

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

CAR-T in Myeloma: the Saudi Guidelines.

https://t.co/gKNMZM9gzh

[Saudi Myeloma المجموعة السعودية لأبحاث المايلوما @SaudiMyeloma]

Before the end of 2025, Cilta-cel (CARVYKTI), a groundbreaking CAR-T cell therapy, launches in Saudi Arabia!

Join us for an exclusive event on Sunday at 8 PM to learn how this innovative treatment is transforming lives for patients with relapsed or refractory MM.

[Vincent Rajkumar @VincentRK]

Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma.

It is the 3rd BCMA bispecific antibody approved for myeloma. I welcome the choice that patients and physicians have. https://t.co/UoxkzsSHZ7

[Ghazi Alotaibi @Ghazialot]

A proud moment!
After 1.5 years of dedication, both Saudi Myeloma Guidelines—for NDMM and RR myeloma—have been officially accepted in CLML.
A huge thank you to the outstanding team at the Saudi Myeloma Working Group.
A national milestone for myeloma care in Saudi Arabia. 🇸🇦📄💪